TREVENTIS Corporation pre clinical candidate TRV 101 demonstrates significant reduction in both amyloid beta and tau toxic aggregates in animal models of Alzheimer's disease

Jul 20, 2015, 08:22 ET from TREVENTIS Corporation

PHILADELPHIA, July 20, 2015 /PRNewswire/ -- Treventis Corporation announced today that the Company's pre-clinical candidate TRV 101 has successfully demonstrated significant reduction in the toxic aggregates/ oligomers of both amyloid beta and tau protein in multiple transgenic mouse models of Alzheimer's Disease (AD). Using industry standard mouse models of amyloid beta (APP/PS1) and tau (rTg4510), a reduction of ~ 30-40% in both tau and amyloid beta oligomers was observed in the brain following oral administration of TRV 101 over a 3-7 day period.

"Toxic oligomers or aggregates of beta-amyloid and tau protein are known to have synergistic and pathogenic roles in the progression of Alzheimer's Disease. These data on TRV 101 show that it is possible to target and reduce both of these protein with a single small molecule, which is a significant advance for the company and the field of Alzheimer's Disease research," said Sean Cunliffe, CEO of Treventis.

TRV 101 is an orally bioavailable, brain-penetrant small molecule that was discovered using a proprietary computational model known as "CCM" (Common Conformational Morphology). The model simulates the earliest phase of protein misfolding and self-association, the process by which both amyloid and tau oligomers are formed. Using this technology, the company has conducted lead optimization on several CCM-identified compounds that have subsequently demonstrated efficacy in multiple animal models of AD. TRV 101 is well tolerated in mice.

TRV 101 is currently being advanced as a potential IND candidate through the support of the Wellcome Trust, with a Phase 1 clinical trial planned for late 2016.

About TREVENTIS Corporation 
TREVENTIS is headquartered in Southeastern Pennsylvania and has research operations in Halifax and Toronto, Canada. The company is focused on the discovery and development of disease-modifying small molecule drugs for a variety of dementias including Alzheimer's. In addition to its therapeutic programs, TREVENTIS has a novel approach to the development of diagnostics for early diagnosis and monitoring treatment effects in Alzheimer's disease.

Contact:
Sean. Cunliffe
TREVENTIS, CEO
Phone: 610-525-7296
scunliffe@treventis.com

 

Photo - http://photos.prnewswire.com/prnh/20150715/237331
Logo - http://photos.prnewswire.com/prnh/20150715/237332LOGO 

SOURCE TREVENTIS Corporation



RELATED LINKS

http://www.TREVENTIS.com